ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis

Endocrine therapy represents the cornerstone of treatment in hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (mBC). The natural course of this disease is marked by endocrine resistance, mainly due to Estrogen Receptor 1 (ESR1) acquired mutations. The aim of this study is to e...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Urso, Loredana, Vernaci, Grazia, Carlet, Jessica, Lo Mele, Marcello, Fassan, Matteo, Zulato, Elisabetta, Faggioni, Giovanni, Menichetti, Alice, Di Liso, Elisabetta, Griguolo, Gaia, Falci, Cristina, Conte, Pierfranco, Indraccolo, Stefano, Guarneri, Valentina, Dieci, Maria Vittoria
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2021
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7991720/
https://ncbi.nlm.nih.gov/pubmed/33777770
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.625636
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars